Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A I / II Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetic Characteristics and Efficacy of MAX-40279 (Multi-target Tyrosine Kinase Inhibitor) Combined With KN046 (Anti-PD-L1 / CTLA-4 Bispecific Antibody) in Patients With Advanced / Metastatic Solid Tumors

NCT05425602 is registered in ClinicalTrials.gov with Maxinovel Pty., Ltd. as lead sponsor.

NCT NCT05425602
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05425602 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A I / II Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetic Characteristics and Efficacy of MAX-40279 (Multi-target Tyrosine Kinase Inhibitor) Combined With KN046 (Anti-PD-L1 / CTLA-4 Bispecific Antibody) in Patients With Advanced / Metastatic Solid Tumors
Lead sponsor
Maxinovel Pty., Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
July 31, 2022
Completion date
December 30, 2024
Enrollment
108 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced / metastatic solid tumors